-
1 week ago | 
urologytimes.com | Stephen J. Freedland |Benjamin P. Saylor
A recent study examined the relationship between randomized controlled trials and real-world efficacy of prostate cancer treatments.1 Investigators found that benefits of treatments that are observed in trials also appear in the real world. In a recent interview with Urology Times®, study author Stephen J. Freedland, MD, discussed the findings, one of which was that real-world overall survival gains appeared to increase with the duration a new therapy was on the market.
-
1 week ago | 
urologytimes.com | Stephen J. Freedland |Benjamin P. Saylor
Findings from a review of randomized clinical trials (RCTs) and real-world efficacy of prostate cancer treatments indicate that RCTs may slightly underestimate the benefits of the treatments.1“When you conduct a phase 3 clinical trial, obviously it's a select group of patients that go on those trials.
-
Jul 17, 2024 | 
onclive.com | Stephen J. Freedland |Eleni Efstathiou
OpinionVideoJuly 17, 2024Author(s):Key opinion leaders outline a case study of a patient with metastatic castration-sensitive prostate cancer, detailing the chosen treatment approaches and the overall outcome of the case. Video content above is prompted by the following questions:What is your initial impression of this patient and their risk stratification? What biomarker testing and imaging would you recommend? How would you assess the burden and distribution of metastatic disease?
-
Jul 17, 2024 | 
onclive.com | Stephen J. Freedland |Eleni Efstathiou
OpinionVideoJuly 17, 2024Author(s):Experts offer concluding remarks on castration-sensitive prostate cancer, sharing their perspectives on the evolving field and expressing their aspirations for future advancements in disease treatment. Video content above is prompted by the following questions:How do you foresee the early treatment paradigm for CSPC evolving in the coming years? Are there other novel agents you're excited about in development?
-
Jul 10, 2024 | 
onclive.com | Stephen J. Freedland |Eleni Efstathiou
Experts present a case study of a patient with non-metastatic castration-sensitive prostate cancer exhibiting rapid PSA doubling, highlighting the clinical implications and potential treatment considerations.
-
Jul 10, 2024 | 
onclive.com | Stephen J. Freedland |Eleni Efstathiou
OpinionVideoJuly 10, 2024Author(s):Specialists examine non-metastatic castration-sensitive prostate cancer cases, evaluating the significance of PSA doubling time and the reliability of biomarkers in risk assessment for these patients. Dr. Efstathiou asks Dr. Freedland: In evaluating non-metastatic CSPC cases, what role does PSA doubling time play in your risk assessment? At what PSA doubling time thresholds do treatment recommendations change?
-
Jul 3, 2024 | 
onclive.com | Stephen J. Freedland |Eleni Efstathiou
Author(s):Prostate cancer experts analyze the EMBARK trial, emphasizing the potential impact of an androgen receptor inhibitor in the treatment of non-metastatic castration-sensitive prostate cancer. Dr. Efstathiou asks Dr. Freedland: Enzalutamide is currently the only androgen receptor inhibitor approved for non-metastatic CSPC. Can you summarize the key data from the EMBARK trial supporting its use in this setting?
-
Jul 3, 2024 | 
onclive.com | Stephen J. Freedland |Eleni Efstathiou
Author(s):Key opinion leaders examine the treatment landscape for castration-sensitive prostate cancer, highlighting prevalent first-line approaches and discussing the role of androgen deprivation therapy in the treatment paradigm. Dr. Freedland asks Dr. Efstathiou: Please review the current treatment landscape for CSPC. What are the main therapeutic approaches typically utilized for these patients? What role does androgen deprivation therapy alone play, and in what settings?
-
Jun 26, 2024 | 
onclive.com | Stephen J. Freedland |Eleni Efstathiou
The panel of prostate cancer experts explores risk stratification methodologies and prognostic markers for castration-sensitive prostate cancer, emphasizing crucial factors that influence patient categorization and treatment decisions.
-
Jun 26, 2024 | 
onclive.com | Stephen J. Freedland |Eleni Efstathiou
OpinionVideoJune 26, 2024Author(s):Key opinion leaders examine the principles and advantages of early intervention strategies for patients with castration-sensitive prostate cancer. Dr. Efstathiou asks Dr. Freedland:Let's start by discussing the importance of early intervention in castration-sensitive prostate cancer (CSPC). What are the potential benefits of treating patients earlier in their disease course? How does early intervention impact long-term outcomes and quality of life?
